Effect of Hashimoto thyroiditis on low‐dose radioactive‐iodine remnant ablation. (15th July 2015)

• Record Type: Journal Article
• Authors: Kwon, Hyungju; Choi, June Young; Moon, Jae Hoon; Park, Hyo Jin; Lee, Won Woo; Lee, Kyu Eun
• Is Part Of: Head & neck. Volume 38(2016)Supplement 1
• Page Start: E730
• Page End: E735
• Publication Date: 2015-07-15
• Subjects: radioiodine -- ablation -- low dose -- papillary thyroid carcinoma -- Hashimoto thyroiditis; Head -- Diseases -- Periodicals; Neck -- Diseases -- Periodicals; Head -- Periodicals; Neck -- Periodicals; Face -- Periodicals; 617.51059
• DOI: 10.1002/hed.24080
• Languages: English
• ISSNs: 1043-3074

Abstract

Abstract: Background: Radioactive‐iodine remnant ablation is an integral part of the papillary thyroid carcinoma (PTC) treatment. Although a minimum dose is usually recommended, there is controversy as to whether the low‐dose (1100 MBq) radioactive‐iodine remnant ablation is adequate for selected patients. Methods: A retrospective cohort study was conducted on 691 patients. Patients with no remnant thyroid on the follow‐up whole body scan and low stimulated thyroglobulin (sTg) level (<2.0 ng/mL) were deemed as successful treatment cases. Results: Initial low‐dose radioactive‐iodine remnant ablation was successful in 431 patients (62.3%). Multivariate analysis demonstrated a negative correlation between successful radioactive‐iodine remnant ablation and coexisting Hashimoto thyroiditis based on histopathology diagnosis (odds ratio [OR] = 3.23; p < .001) as well as elevated preablation sTg (OR = 1.24; p < .001). Conclusion: Our data suggest that coexisting Hashimoto thyroiditis and elevated sTg are negative predictive factors for successful low‐dose radioactive‐iodine remnant ablation treatment. An appropriate risk‐adjusted approach may improve the efficacy of radioactive‐iodine remnant ablation treatment. © 2015 Wiley Periodicals, Inc. Head Neck 38 : E730–E735, 2016